ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Orchard Therapeutics plc (NASDAQ: ORTX) to Kyowa Kirin Co., Ltd. is fair to Orchard shareholders. Under the terms of the agreement, Kyowa Kirin would acquire all Orchard’s American Depositary Shares (ADS) at a price of $16.00 per ADS in cash. Additionally, a non-transferable contingent value right will be distributed to Orchard shareholders, entitling the holders to a cash payment of $1.00 per ADS related to the approval of OTL-200 for the treatment of MLD in the U.S.

Halper Sadeh encourages Orchard shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Orchard and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Orchard shareholders; (2) determine whether Kyowa Kirin is underpaying for Orchard; and (3) disclose all material information necessary for Orchard shareholders to adequately assess and value the merger consideration. On behalf of Orchard shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Orchard shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.